ERBB2 and non-small cell lung carcinoma: A Chinese multi-center cohort study also revealed the comprehensive profiles and real-world evidence of HER2 TMD mutation treatment in NSCLC, with a total prevalence of 0.18% (14/7812) and 0.14% (11/7812) for the p.V659E alteration.